Pro-Dex Inc
$ 65.56
0.12%
07 Aug - close price
- Market Cap 209,317,000 USD
- Current Price $ 65.56
- High / Low $ 68.10 / 65.10
- Stock P/E 18.06
- Book Value 14.14
- EPS 3.63
- Next Earning Report 2026-09-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.30 %
- 52 Week High 68.99
- 52 Week Low 23.47
About
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company is headquartered in Irvine, California.
Analyst Target Price
$70.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-01-29 | 2025-10-30 | 2025-09-04 | 2025-05-01 | 2025-01-30 | 2024-10-31 | 2024-09-05 | 2024-05-02 | 2024-02-08 | 2023-10-13 | 2023-09-29 |
| Reported EPS | 1.2 | 0.6619 | 1.4 | 0.36 | 0.85 | 0.61 | 0.75 | 0.46 | 0.19 | 0.14 | -0.17 | 0.42 |
| Estimated EPS | 0.62 | 0.59 | 0.5 | 0.47 | 0.47 | 0.38 | 0.29 | 0.35 | 0.35 | 0.35 | 0.32 | 0.33 |
| Surprise | 0.58 | 0.0719 | 0.9 | -0.11 | 0.38 | 0.23 | 0.46 | 0.11 | -0.16 | -0.21 | -0.49 | 0.09 |
| Surprise Percentage | 93.5484% | 12.1864% | 180% | -23.4043% | 80.8511% | 60.5263% | 158.6207% | 31.4286% | -45.7143% | -60% | -153.125% | 27.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-09-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PDEX
2026-07-25 11:13:27
Pro-Dex Inc. (PDEX) is trading at $54.930, up 0.48%, with a market capitalization of $175.38 million. The company, which specializes in surgical drivers and air motors, shows strong fundamentals including consistent revenue growth and high profit growth, despite recent institutional selling. Analysts currently rate the stock as a "Buy" with a target price of $70.00.
2026-07-15 21:40:35
Angelita Rebamontan Domingo, a director at PRO DEX INC (NASDAQ:PDEX), recently sold 998 shares of the company's common stock for $47.24 per share, totaling $47,145. Following the transaction, Domingo directly holds 18,779 shares, and the stock has since climbed 23%. The company's stock is currently on InvestingPro's Most Overvalued list, though it maintains a "GREAT" financial health score and trades at a PEG ratio of 0.53.
2026-07-14 21:44:55
Angelita Rebamontan Domingo, a director at PRO DEX INC (NASDAQ: PDEX), recently sold 998 shares of the company's common stock for $47,145. The transaction occurred on March 16, 2026, at $47.24 per share. Following the sale, Domingo directly holds 18,779 shares, and the stock has since increased by 23% to $58.26, while analysts consider it overvalued despite a "GREAT" financial health score and an attractive PEG ratio of 0.53.
2026-07-14 21:44:55
A director at Pro-Dex Inc. (NASDAQ: PDEX), Domingo Angelita Rebamontan, sold 998 shares of common stock in an open-market transaction on March 16, 2026, at a price of $47.24 per share. Following this sale, the director directly holds 18,779 shares of Pro-Dex common stock. The transaction, categorized as a net sell of $47,146, was reported in a Form 4 SEC filing.
2026-07-14 21:44:55
This article from Investing.com announces the filing of Form 4 for Pro-Dex Inc. on July 14. The concise piece indicates a financial disclosure but provides no further details on the content of the form. It notes the stock symbol PDEX is down 5.35%.
2026-07-02 05:09:13
This article provides current stock information for Pro-Dex Inc New (PDEX), including its latest trading price of $62.03, recent performance, and key market data. It also details the company's business activities as a designer and manufacturer of powered surgical instruments and provides a guide on how to buy PDEX stock on MEXC. The FAQ section offers further insights into its market classification, financial metrics, and dividend policy.
